Palatin Technologies, Inc. reported a net loss of $8.4 million for the fiscal year ending June 30, 2026, a decrease from a net loss of $17.3 million in the previous fiscal year. The company recognized $13.2 million in collaboration and license revenue, primarily from agreements with Boehringer Ingelheim and Altanispac Labs, marking a significant increase from no revenue in the prior year. This revenue included $9.4 million from the Boehringer Ingelheim Agreement and $3.8 million from the Altanispac Agreement, reflecting the company's strategic focus on advancing its melanocortin receptor-targeted compounds for various medical conditions.
In terms of operational changes, Palatin Technologies has made significant strides in its product development pipeline. The company is advancing its MC4R agonist programs aimed at treating obesity and related disorders, with plans for a Phase 1 clinical study for a long-acting peptide agonist expected to begin in the first half of 2027. Additionally, the company has retained rights to PL9643, a treatment for dry eye disease, which has been sublicensed to Altanispac Labs. The collaboration with Boehringer Ingelheim includes potential milestone payments of up to €280 million (approximately $328 million), which could significantly impact future revenues.
Palatin's total research and development expenses decreased to $12.4 million in fiscal 2026 from $14.9 million in fiscal 2025, primarily due to reduced spending on its MC4R programs. The company reported a cumulative deficit of $467.5 million as of June 30, 2026, and has indicated that it will require additional funding to continue its development efforts. As of the same date, Palatin had cash and cash equivalents of $7.5 million, which management believes may not be sufficient to fund operations for the next twelve months without securing additional financing.
The company employed 25 full-time staff as of September 25, 2026, with a focus on research and development. Palatin's strategic direction includes forming collaborations and licensing arrangements to enhance its product development capabilities. However, the company faces substantial risks, including the need for additional financing, potential delays in clinical trials, and the uncertainty of achieving regulatory approvals. The outlook remains cautious, with management acknowledging substantial doubt about the company's ability to continue as a going concern without securing further funding.
About PALATIN TECHNOLOGIES INC
Palatin Technologies, Inc. is a biopharmaceutical company focused on developing receptor-specific medicines targeting the melanocortin receptor system. Its products aim to treat inflammatory, autoimmune, metabolic, and rare diseases, including obesity, dry eye disease, and inflammatory bowel conditions. The company leverages proprietary peptides and small molecules, collaborates with industry partners, and seeks regulatory approval to commercialize innovative therapies with broad therapeutic potential.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov